Quick Takeaways:  Why It Matters?   Genflow’s early canine SIRT6 data are strong enough that big animal‑health players now want a closer look, but not yet strong enough for anyone to sign a deal.  The expanded web of NDAs suggests real strategic interest in longevity‑focused pet gene therapy and sets Genflow up for potential licensing or co‑development talks once it can show more mature, durable...